Compare ASTRAZENECA PHARMA with Unichem Lab - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

ASTRAZENECA PHARMA vs UNICHEM LAB - Comparison Results

ASTRAZENECA PHARMA     Change

AstraZeneca Pharma India Limited (APIL) is a 90% subsidiary of the UK based AstraZeneca Pharmaceuticals, which is one of the world's leading pharma companies. APIL has interests in the six crucial areas of cardiovascular, respiratory, maternal health... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    ASTRAZENECA PHARMA UNICHEM LAB ASTRAZENECA PHARMA/
UNICHEM LAB
 
P/E (TTM) x 137.9 -41.4 - View Chart
P/BV x 38.7 1.0 3,810.9% View Chart
Dividend Yield % 0.0 1.4 -  

Financials

 ASTRAZENECA PHARMA   UNICHEM LAB
EQUITY SHARE DATA
    ASTRAZENECA PHARMA
Mar-18
UNICHEM LAB
Mar-19
ASTRAZENECA PHARMA/
UNICHEM LAB
5-Yr Chart
Click to enlarge
High Rs1,278292 437.7%   
Low Rs883182 484.9%   
Sales per share (Unadj.) Rs228.4167.7 136.2%  
Earnings per share (Unadj.) Rs10.4-3.6 -285.5%  
Cash flow per share (Unadj.) Rs16.35.9 273.7%  
Dividends per share (Unadj.) Rs04.00 0.0%  
Dividend yield (eoy) %01.7 0.0%  
Book value per share (Unadj.) Rs98.8372.3 26.5%  
Shares outstanding (eoy) m25.0070.38 35.5%   
Bonus/Rights/Conversions -ESOP-  
Price / Sales ratio x4.71.4 334.6%   
Avg P/E ratio x104.2-65.3 -159.7%  
P/CF ratio (eoy) x66.439.9 166.6%  
Price / Book Value ratio x10.90.6 1,717.9%  
Dividend payout %0-110.2 0.0%   
Avg Mkt Cap Rs m27,00816,680 161.9%   
No. of employees `0001.42.6 52.1%   
Total wages/salary Rs m1,5352,393 64.2%   
Avg. sales/employee Rs Th4,210.94,535.2 92.9%   
Avg. wages/employee Rs Th1,132.2919.8 123.1%   
Avg. net profit/employee Rs Th191.1-98.2 -194.6%   
INCOME DATA
Net Sales Rs m5,71011,801 48.4%  
Other income Rs m123984 12.4%   
Total revenues Rs m5,83312,785 45.6%   
Gross profit Rs m463-835 -55.4%  
Depreciation Rs m147674 21.9%   
Interest Rs m075 0.0%   
Profit before tax Rs m438-600 -73.0%   
Minority Interest Rs m00-   
Prior Period Items Rs m01 0.0%   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m179-343 -52.1%   
Profit after tax Rs m259-256 -101.4%  
Gross profit margin %8.1-7.1 -114.6%  
Effective tax rate %40.857.3 71.3%   
Net profit margin %4.5-2.2 -209.6%  
BALANCE SHEET DATA
Current assets Rs m3,20920,384 15.7%   
Current liabilities Rs m2,0705,029 41.1%   
Net working cap to sales %20.0130.1 15.3%  
Current ratio x1.64.1 38.3%  
Inventory Days Days72105 69.0%  
Debtors Days Days35135 25.9%  
Net fixed assets Rs m7909,023 8.8%   
Share capital Rs m50141 35.5%   
"Free" reserves Rs m2,41926,058 9.3%   
Net worth Rs m2,46926,199 9.4%   
Long term debt Rs m00-   
Total assets Rs m4,60531,496 14.6%  
Interest coverage xNM-7.0-  
Debt to equity ratio x00-  
Sales to assets ratio x1.20.4 330.9%   
Return on assets %5.6-0.6 -982.6%  
Return on equity %10.5-1.0 -1,075.8%  
Return on capital %17.7-2.0 -887.2%  
Exports to sales %069.4 0.0%   
Imports to sales %00-   
Exports (fob) Rs mNA8,188 0.0%   
Imports (cif) Rs mNANA-   
Fx inflow Rs m3008,188 3.7%   
Fx outflow Rs m2,015596 338.1%   
Net fx Rs m-1,7157,592 -22.6%   
CASH FLOW
From Operations Rs m88-3,278 -2.7%  
From Investments Rs m-94-2,860 3.3%  
From Financial Activity Rs mNA-24 0.0%  
Net Cashflow Rs m-6-4,690 0.1%  

Share Holding

Indian Promoters % 0.0 50.1 -  
Foreign collaborators % 75.0 0.0 -  
Indian inst/Mut Fund % 0.3 15.1 2.0%  
FIIs % 15.7 3.0 523.3%  
ADR/GDR % 0.0 0.0 -  
Free float % 9.1 31.7 28.7%  
Shareholders   12,856 20,176 63.7%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare ASTRAZENECA PHARMA With:   SANOFI INDIA  ABBOTT INDIA  STRIDES PHARMA SCIENCE  CIPLA  TORRENT PHARMA  

Compare ASTRAZENECA PHARMA With:   MYLAN (US)  ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Sensex Opens Lower Tracking Mixed Global Cues; Tata Motors & Sun Pharma Top Losers(09:30 am)

Asian share markets are trading on a mixed note today. All eyes are on the US Federal Reserve policy outcome due later today.

Related Views on News

METROPOLIS HEALTHCARE Share Price Up by 6%; BSE HEALTHCARE Index Down 0.7% (Market Updates)

Jan 27, 2021 | Updated on Jan 27, 2021

METROPOLIS HEALTHCARE share price is trading up by 6% and its current market price is Rs 2,158. The BSE HEALTHCARE is down by 0.7%. The top gainers in the BSE HEALTHCARE Index are METROPOLIS HEALTHCARE (up 5.8%) and ASTRAZENECA PHARMA (up 6.8%). The top losers are ERIS LIFESCIENCES and BLISS GVS PHARMA .

ADVANCED ENZYME TECHNOLOGIES Share Price Up by 5%; BSE HEALTHCARE Index Down 0.7% (Market Updates)

Jan 27, 2021 | Updated on Jan 27, 2021

ADVANCED ENZYME TECHNOLOGIES share price is trading up by 5% and its current market price is Rs 325. The BSE HEALTHCARE is down by 0.7%. The top gainers in the BSE HEALTHCARE Index are ADVANCED ENZYME TECHNOLOGIES (up 5.1%) and ASTRAZENECA PHARMA (up 6.7%). The top losers are APOLLO HOSPITALS and ERIS LIFESCIENCES .

ASTRAZENECA PHARMA Share Price Up by 6%; BSE HEALTHCARE Index Down 0.6% (Market Updates)

Jan 27, 2021 | Updated on Jan 27, 2021

ASTRAZENECA PHARMA share price is trading up by 6% and its current market price is Rs 3,840. The BSE HEALTHCARE is down by 0.6%. The top gainers in the BSE HEALTHCARE Index is ASTRAZENECA PHARMA (up 6.1%). The top losers are ABBOTT INDIA (down 0.1%) and SYNGENE INTERNATIONAL (down 0.1%).

ASTRAZENECA PHARMA Announces Quarterly Results (1QFY21); Net Profit Down 13.4% (Quarterly Result Update)

Sep 22, 2020 | Updated on Sep 22, 2020

For the quarter ended June 2020, ASTRAZENECA PHARMA has posted a net profit of Rs 186 m (down 13.4% YoY). Sales on the other hand came in at Rs 2 bn (down 5.4% YoY). Read on for a complete analysis of ASTRAZENECA PHARMA's quarterly results.

ASTRAZENECA PHARMA Announces Quarterly Results (4QFY20); Net Profit Down 2.5% (Quarterly Result Update)

May 20, 2020 | Updated on May 20, 2020

For the quarter ended March 2020, ASTRAZENECA PHARMA has posted a net profit of Rs 96 m (down 2.5% YoY). Sales on the other hand came in at Rs 2 bn (up 2.4% YoY). Read on for a complete analysis of ASTRAZENECA PHARMA's quarterly results.

More Views on News

Most Popular

Time to Book Profits in Pharma Stocks(Fast Profits Daily)

Jan 15, 2021

In this video, I'll show you why it might be the right time to take money of the table in pharma stocks.

Smallcap Stocks: Your Best Bet for 2021 and Beyond(Profit Hunter)

Jan 15, 2021

The pandemic failed to thwart Richa's investing success formula for 2020.

One Chart to See Before You Sell(Fast Profits Daily)

Jan 22, 2021

In this video, I'll show you a crucial chart that you need to check before you decide to sell any stock or index.

Invest in the Multibaggers of 2021 and Beyond(Profit Hunter)

Jan 21, 2021

Our ace stock picker is ready to capitalise on a big growth opportunity.

More

India's #1 Trader
Reveals His Secrets

Secret To Increasing Your Trading Profits Today
Get this Special Report,
The Secret to Increasing Your Trading Profits Today, Now!
We will never sell or rent your email id.
Please read our Terms

ASTRAZENECA PHARMA SHARE PRICE


Jan 27, 2021 12:02 PM

TRACK ASTRAZENECA PHARMA

  • Track your investment in ASTRAZENECA PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON ASTRAZENECA PHARMA

ASTRAZENECA PHARMA - NOVARTIS COMPARISON

COMPARE ASTRAZENECA PHARMA WITH

MARKET STATS